Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01277341 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis
A Phase 2 study of Seasonal Allergic Rhinitis, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 601
- Enrollment target
- 1
- Study location
NCT01277341 is a Phase 2 study of Seasonal Allergic Rhinitis that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 601 participants, roughly in line with the 631-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT01277341, a Phase 2 study of Seasonal Allergic Rhinitis, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 601 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an efficacy study of bepotastine besilate nasal spray in seasonal allergic rhinitis.
Conditions Studied
Interventions
- DRUG Placebo Nasal Spray
- DRUG Bepotastine Besilate Nasal Spray 2% Twice a day
- DRUG Bepotastine Besilate Nasal Spray 3% Twice a day
- DRUG Bepotastine Besilate Nasal Spray 4% Twice a day
Study Locations (1)
California
- ISTA Pharmaceuticals, Inc. - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 601 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01277341
The ClinicalTrials.gov registry entry for NCT01277341 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 601 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 631-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Seasonal Allergic Rhinitis appearing as the primary indexed condition, and to 4 interventions - of which Placebo Nasal Spray is the first listed.
NCT01277341 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01277341 about?
NCT01277341 is a clinical study titled "Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis". This is an efficacy study of bepotastine besilate nasal spray in seasonal allergic rhinitis.
What is the current status of trial NCT01277341?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 601 participants. The study started on 2010-12. Estimated completion is 2011-05.
What conditions does trial NCT01277341 study?
This clinical trial studies the following conditions: Seasonal Allergic Rhinitis.
What interventions are being tested in trial NCT01277341?
The interventions under investigation include: Placebo Nasal Spray (DRUG), Bepotastine Besilate Nasal Spray 2% Twice a day (DRUG), Bepotastine Besilate Nasal Spray 3% Twice a day (DRUG), Bepotastine Besilate Nasal Spray 4% Twice a day (DRUG).
Who is sponsoring clinical trial NCT01277341?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01277341 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seasonal Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™
COMPLETED · Phase 2
-
Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis
COMPLETED · Phase 2
-
Clinical Trial of STAHIST in Seasonal Allergic Rhinitis (SAR) Subjects
COMPLETED · Phase 2
-
Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)
COMPLETED · Phase 3
-
Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)
COMPLETED · Phase 3
-
Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.